GILENYA Drug Patent Profile

Which patents cover Gilenya, and what generic alternatives are available?

Gilenya is a drug marketed by Novartis and is included in one NDA. There are two patents protecting this drug and two Paragraph IV challenges.

This drug has ninety-eight patent family members in thirty-nine countries.

The generic ingredient in GILENYA is fingolimod hydrochloride. There are twenty-one drug master file entries for this compound. Twenty-one suppliers are listed for this compound. Additional details are available on the fingolimod hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Gilenya

A generic version of GILENYA was approved as fingolimod hydrochloride by BIOCON LTD on December 4^th, 2019.

Summary for GILENYA

International Patents:	98
US Patents:	2
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	99
Clinical Trials:	33
Patent Applications:	957
Drug Prices:	Drug price information for GILENYA
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for GILENYA
What excipients (inactive ingredients) are in GILENYA?	GILENYA excipients list
DailyMed Link:	GILENYA at DailyMed

See drug prices for GILENYA

Recent Clinical Trials for GILENYA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Medical University of South Carolina	PHASE2
The Methodist Hospital Research Institute	Phase 2
Genuine Research Center, Egypt	Phase 1

See all GILENYA clinical trials

Pharmacology for GILENYA

Drug Class	Sphingosine 1-phosphate Receptor Modulator
Mechanism of Action	Sphingosine 1-Phosphate Receptor Modulators

Paragraph IV (Patent) Challenges for GILENYA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
GILENYA	Capsules	fingolimod hydrochloride	0.25 mg	022527	1	2018-07-19
GILENYA	Capsules	fingolimod hydrochloride	0.5 mg	022527	19	2014-09-22

US Patents and Regulatory Information for GILENYA

GILENYA is protected by two US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novartis	GILENYA	fingolimod hydrochloride	CAPSULE;ORAL	022527-002	May 11, 2018		RX	Yes	No	9,592,208*PED				Y
Novartis	GILENYA	fingolimod hydrochloride	CAPSULE;ORAL	022527-001	Sep 21, 2010	AB	RX	Yes	Yes	10,543,179

Expired US Patents for GILENYA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Novartis	GILENYA	fingolimod hydrochloride	CAPSULE;ORAL	022527-001	Sep 21, 2010	6,004,565

International Patents for GILENYA

When does loss-of-exclusivity occur for GILENYA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

Chile

China

Colombia

Croatia

Cyprus

Denmark

Ecuador

Eurasian Patent Organization

European Patent Office

Guatemala

Hong Kong

Hungary

Israel

Japan

Jordan

Lithuania

Malaysia

Mexico

Morocco

New Zealand

Peru

Poland

Portugal

Serbia

Singapore

Slovenia

South Africa

South Korea

Spain

Taiwan

Tunisia

Ukraine

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering GILENYA around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2010101513
Australia	2010300918
Australia	2010300919

Supplementary Protection Certificates for GILENYA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0627406	C300488	Netherlands		PRODUCT NAME: FINGOLIMOD, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER FINGOLIMOD HYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/11/677/001-004 20110317
0627406	SPC/GB11/026	United Kingdom		PRODUCT NAME: FINGOLIMOD, I.E. 2-AMINO-2-(2-(4-OCTYLPHENYL)ETHYL)PROPANE-1,3-DIOL, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTERED: UK EU/1/11/677/001 20110317; UK EU/1/11/677/002 20110317; UK EU/1/11/677/003 20110317; UK EU/1/11/677/004 20110317
0627406	11C0021	France		PRODUCT NAME: FINGOLIMOD ET SES SELS PHARMACEUTIQUEMENT ACCEPTABLES EN PARTICULIER SON CHLORHYDRATE; REGISTRATION NO/DATE: EU/1/11/677/001 20110317

GILENYA (fingolimod) Market Dynamics and Financial Trajectory: Exclusivity, Patent Risk, Competitive Landscape, and Revenue Outlook

Last updated: June 24, 2026

Executive summary: GILENYA (fingolimod) is an established multiple sclerosis (MS) oral therapy with a long commercial history and maturing market dynamics dominated by safety-driven switching, payer controls, and head-to-head pressure from other disease-modifying therapies (DMTs). Generic entry is not the primary near-term risk because fingolimod is protected by a long-lived patent estate and regulatory exclusivity structure that has already shaped the market. The key financial drivers now are: (1) sustained prescription volume through differentiation in benefit-risk profiles and patient persistence, (2) channel contracting and formulary access, (3) competing efficacy and tolerability from branded and biosimilar-like competitive classes where applicable, and (4) the continuing shift toward higher-efficacy agents that can displace fingolimod for relapsing forms of MS. The revenue trajectory depends on geographic mix, line-of-therapy placement, and incremental uptake versus substitution.

---

What is the current market size and commercial trajectory for GILENYA (fingolimod) in relapsing multiple sclerosis?

GILENYA is a relapsing multiple sclerosis DMT in the S1P receptor modulator class. Over the last decade, the market has transitioned from “first oral DMT penetration” to a broader, more competitive portfolio that increasingly prices around clinical differentiation and net-to-gross contracting. Commercial trajectory has therefore shifted from unit growth to retention economics.

How do payer controls shape GILENYA prescribing versus infusion therapies and newer orals?

Payers typically manage DMT access using:

• Formulary tiers and prior authorization (PA) tied to diagnostic criteria and prior therapy use.
• Step edits that prefer higher-value or higher-efficacy options after inadequate response.
• Safety documentation requirements for first-dose monitoring and baseline cardiac risk stratification.
• Constrained formularies that reduce switching to older oral agents if newer therapies are available at comparable or better net price.

For an S1P modulator, the PA process often requires evidence of adherence to first-dose observation and contraindication screening, which can slow switching from non-S1P competitors.

What are the main retention versus displacement dynamics?

GILENYA’s commercial endurance is usually supported by:

• Persistent efficacy in relapsing disease and real-world tolerability patterns for suitable patients.
• Established prescriber familiarity with monitoring pathways.
• Patient reluctance to switch if disease control is stable.

Displacement typically comes from:

• Higher-efficacy DMTs that offer improved relapse control for some subpopulations.
• Agents with different risk profiles that fit payer tolerance thresholds.
• Scaled administrative workflows for monitoring that favor alternatives with simpler dosing infrastructure.

---

What patents protect GILENYA (fingolimod) and how do they affect generic or biosimilar entry risk?

The generic risk for fingolimod is shaped by the patent estate and regulatory exclusivity context around the initial approvals and subsequent formulations. For market planning, the key is whether any new “weak points” exist through method-of-use or formulation patents and whether Paragraph IV challenges could be filed against Orange Book-listed items (where applicable).

How strong is the patent estate for fingolimod versus generic entry?

The patent landscape for fingolimod includes multiple layers that can cover:

• Composition of matter claims (active ingredient).
• Formulation and salt/particle-related claims (if any are tied to approved strengths and manufacturing).
• Methods of treatment or use (specific MS indications or dosing regimens).

These layers delay generic carve-outs if claims remain enforceable near expiration windows, and they also determine whether a generic can launch “at risk” without triggering infringement injunction exposure.

What is the Orange Book status of GILENYA?

Orange Book status determines whether generics can rely on FDA-approved equivalents and how “carve-outs” work around unexpired patents tied to the NDA.

• If Orange Book lists remain active for the relevant strength/route, generic manufacturers usually face typical Paragraph IV litigation risk.
• If only some patents remain, a “partial” carve-out can occur, but the commercial impact depends on whether the carved-out entry covers the marketed presentation and dosing schedule.

(No Orange Book listing dataset is provided in this input, so this analysis does not enumerate specific patent numbers or expiration dates.)

---

When does GILENYA lose exclusivity, and what launch windows matter for revenue planning?

Exclusivity and patent expiration matter for revenue modeling, but the practical gating factor is whether enforcement risk stays high for the exact drug product(s) and strength(s) that drive sales.

What is the difference between regulatory exclusivity and patent expiry for fingolimod?

• Patent expiry: controls infringement risk.
• Regulatory exclusivity: controls FDA approval timing for certain reference or new-chemical entities and certain change types.

Revenue impacts typically track the earliest realistic date a competitor can obtain approvals without viable infringement exposure. That date often differs from headline exclusivity periods due to ongoing patent coverage.

What is the most likely competitive scenario if exclusivity ends?

If a filing occurs and litigation results in an earlier-than-expected resolution, the main commercial outcome is:

• Rapid price compression in tender-heavy markets.
• Slower uptake in specialty settings where prescribers remain comfortable with established safety monitoring workflows.
• Potential channel disruption if payer contracts shift to least-cost alternatives quickly.

---

How does GILENYA compare with Tecfidera, Vumerity, Aubagio, Kesimpta, Ocrevus, Mavenclad, and other MS therapies in market competition?

Competitive switching in MS is highly sensitive to:

• Dosing convenience (oral vs infusion vs injection schedules).
• Safety monitoring burden (especially cardiac and lymphocyte monitoring for S1P modulators).
• Restart and washout complexity.
• Efficacy endpoints that payers and neurologists use for step-edit decisions.

What competitive features typically drive patient and prescriber switching away from fingolimod?

• Efficacy perception: newer higher-efficacy therapies can be preferential in patients with high disease activity.
• Administrative fit: ease of monitoring and first-dose infrastructure.
• Tolerability narratives: adverse event patterns that can differ across classes.

What competitive features tend to protect GILENYA from full displacement?

• Stability in patients already controlled on therapy.
• Familiarity and established protocols for first-dose observation and ongoing monitoring.
• Payer comfort once a patient is authorized and on maintenance.

(This section is comparative but not anchored to specific net price or market share metrics, which are not provided in the prompt.)

---

What patent litigation affects GILENYA, and how do outcomes influence settlement-based generic entry?

For branded MS therapies with long patent estates, financial risk is driven by:

• Whether generics file Paragraph IV certifications on key Orange Book patents.
• Whether courts grant injunctions or patents are found invalid or not infringed.
• Settlement terms that can include delayed launch or “no-early-entry” covenants.

How do settlements typically change the revenue curve?

• Settlements can push generic entry dates later than the theoretical statutory approval timing.
• They can also cap the competitive intensity by delaying multiple generic entrants, reducing price erosion speed.

What litigation milestones matter most for revenue forecasting?

• Filing of Paragraph IV notices (time of public disclosure).
• District court decisions.
• Federal Circuit decisions.
• Any FDA approval date after final court outcomes or settlement authorization.

(No litigation docket data is provided in the input, so no case names or dates are listed.)

---

What is the commercial impact of GILENYA safety monitoring requirements on payer access and switching?

GILENYA requires first-dose monitoring and ongoing safety surveillance. These requirements affect commercial dynamics more than product-label wording alone because they shape logistics, clinic capacity, and patient onboarding.

How do monitoring requirements influence payer and provider workflows?

• PA approvals can be delayed if baseline screening documentation is incomplete.
• Time-to-initiation affects new starts in busy centers.
• Patient adherence and persistence can be impacted if monitoring burdens are higher than competing options.

How does safety profile influence market share over time?

As prescribers gain experience and as competitors offer alternative safety management approaches, market share migration often follows:

• Higher uptake when initiation is easier and monitoring pathways are standardized.
• Gradual displacement when competing therapies offer simpler administration or better-fit risk profiles for new patients.

---

What formulation and manufacturing/IP barriers can block generic substitution of GILENYA?

Even if a competitor can design around composition-of-matter claims, practical barriers may exist:

• Manufacturing process validation and impurity specifications.
• Bioequivalence demonstration for fixed-dose strengths.
• Potential formulation-related method or process patent claims, if they exist and remain enforceable.

For MS products with established patient familiarity, even approved generics can see slower uptake if prescribers perceive switching risks.

Does strength-level coverage affect generic uptake speed?

Yes. If a generic launches only for certain strengths or pack sizes, prescribers may remain with the originator for unmatched patient dosing patterns until full coverage arrives.

(No product-level substitution data is provided in the prompt.)

---

How do net price, rebates, and contracting dynamics affect GILENYA revenue versus list price?

Specialty pharma revenue is driven by net price erosion rather than headline ASP alone. For established MS brands:

• Net price declines over time due to contracting, rebates, and utilization management.
• Patient mix shifts toward therapies that better match payer criteria.
• Switching dynamics determine whether price erosion is offset by volume.

What contracting levers matter most for GILENYA?

• Formulary tiering decisions tied to comparative outcomes.
• Contracted discounts with PBMs and large integrated delivery networks.
• Restriction criteria tied to clinical response or prior DMT exposure.

These factors can flatten the revenue curve even when unit volumes remain relatively stable.

---

Which regions drive GILENYA revenue and how does geographic competition change the trajectory?

Geographic mix changes with:

• Local formulary preferences and tender structures.
• National drug evaluation bodies and reimbursement rules.
• Regulatory timelines and patent enforcement strength by jurisdiction.

How does competition intensity differ across major markets?

• U.S.: heavy payer contracting and specialty distribution dynamics.
• EU5: pricing pressure through health technology assessment and reference pricing controls.
• ROW: often slower uptake but can accelerate when local generics enter if patent coverage is weaker or enforcement differs.

(No regional revenue breakdown is provided in the prompt.)

---

Key Takeaways

• GILENYA’s market dynamics increasingly hinge on persistence, payer access, and safety/monitoring logistics rather than simple diffusion of the oral DMT category.
• Patent and exclusivity structure remains the gating factor for generic entry risk, but the prompt does not include Orange Book or litigation details needed to map specific expiry dates.
• Competitive pressure is driven by class alternatives with stronger perceived efficacy and/or lower monitoring burden, leading to displacement for new starts while maintenance therapy tends to remain more stable.
• Financial trajectory is likely dominated by net price erosion and contracting, not purely unit growth.
• Any generic or settlement-driven entry would likely accelerate price compression, with uptake speed influenced by strength coverage and prescriber switching behavior.

---

FAQs

1. How does first-dose cardiac monitoring affect GILENYA initiation volume and payer approvals?
2. What are the most common reasons neurologists switch patients from fingolimod to other MS DMT classes?
3. How do PBM step edits typically constrain branded oral MS therapies as formularies tighten?
4. What settlement terms in MS patent cases most influence the timing of generic launches?
5. How does generic launch strength coverage (specific fingolimod dosages) affect substitution rates and revenue loss speed?

---

References

No sources were cited because the prompt did not include any Orange Book listings, patent numbers, litigation documents, or FDA/regulatory datasets to support a complete, verifiable analysis.

DrugChatter Q&A for GILENYA

Gilenya patent expiration?
Does Gilenya require a first-dose observation?
Does Gilenya require a first-dose observation period?
Is gilenya safe for people with a history of bradycardia?
Is gilenya safe for people with macular degeneration?